Decoding inflammation: GARP, miR-142-3-p, and MALAT1 as novel inflammatory biomarkers of IBD

Abstract

Abstract Purpose: Inflammatory bowel disease (IBD) is a life-threatening disorder of the gastrointestinal tract. For the first time, we studied the role of GARP, a crucial regulator of TGF-β synthesis, in Crohn's disease (CD) and ulcerative colitis (UC) patients. We also investigated the upstream regulatory Non-coding RNAs of GARP, namely Lnc-MALAT1 and miR-142-3p. This research sheds light on the mechanisms underlying the development of inflammation in IBD.Methods: A peripheral blood sample was collected from 22 patients with CD, 22 patients with UC, and 22 healthy individuals. PBMCs were isolated, and RNAs were extracted and synthesized into cDNAs. Genes expression was evaluated using the Real-Time PCR method.Results: Our study revealed a decrease in GARP expression in both CD and IBD groups. We also found that the expression of MALAT1 and miR-142-3-p were elevated in CD and IBD groups, contributing to the observed decrease in GARP levels. It also has been discovered that smoking is associated with an increase in MALAT1 expression in all patients.Conclusion: Our research indicates that changes in GARP, MALAT1, and miR-142-3-p levels may be the culprit behind the reduction in TGF-β levels. Moreover, an increase in MALAT1 and miR-142-3-p expression could be responsible for a decrease in GARP levels. These novel biomarkers provide a deeper understanding of the pathways involved in the pathogenesis of IBD and may pave the way for the development of innovative diagnostic or therapeutic approaches.